1. Home
  2. NBIX vs ALGN Comparison

NBIX vs ALGN Comparison

Compare NBIX & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NBIX
  • ALGN
  • Stock Information
  • Founded
  • NBIX 1992
  • ALGN 1997
  • Country
  • NBIX United States
  • ALGN United States
  • Employees
  • NBIX N/A
  • ALGN N/A
  • Industry
  • NBIX Biotechnology: Biological Products (No Diagnostic Substances)
  • ALGN Industrial Specialties
  • Sector
  • NBIX Health Care
  • ALGN Health Care
  • Exchange
  • NBIX Nasdaq
  • ALGN Nasdaq
  • Market Cap
  • NBIX 14.1B
  • ALGN 12.5B
  • IPO Year
  • NBIX 1996
  • ALGN N/A
  • Fundamental
  • Price
  • NBIX $139.41
  • ALGN $132.35
  • Analyst Decision
  • NBIX Strong Buy
  • ALGN Buy
  • Analyst Count
  • NBIX 18
  • ALGN 13
  • Target Price
  • NBIX $161.50
  • ALGN $216.25
  • AVG Volume (30 Days)
  • NBIX 713.3K
  • ALGN 1.3M
  • Earning Date
  • NBIX 10-29-2025
  • ALGN 10-22-2025
  • Dividend Yield
  • NBIX N/A
  • ALGN N/A
  • EPS Growth
  • NBIX 2.97
  • ALGN 0.42
  • EPS
  • NBIX 3.39
  • ALGN 5.92
  • Revenue
  • NBIX $2,509,900,000.00
  • ALGN $3,964,802,000.00
  • Revenue This Year
  • NBIX $20.66
  • ALGN $2.03
  • Revenue Next Year
  • NBIX $14.64
  • ALGN $3.31
  • P/E Ratio
  • NBIX $41.44
  • ALGN $22.14
  • Revenue Growth
  • NBIX 18.42
  • ALGN 0.56
  • 52 Week Low
  • NBIX $84.23
  • ALGN $127.70
  • 52 Week High
  • NBIX $154.61
  • ALGN $262.87
  • Technical
  • Relative Strength Index (RSI)
  • NBIX 53.05
  • ALGN 37.93
  • Support Level
  • NBIX $140.56
  • ALGN $130.84
  • Resistance Level
  • NBIX $144.04
  • ALGN $140.37
  • Average True Range (ATR)
  • NBIX 3.54
  • ALGN 4.02
  • MACD
  • NBIX -0.26
  • ALGN 0.67
  • Stochastic Oscillator
  • NBIX 35.85
  • ALGN 11.74

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

About ALGN Align Technology Inc.

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Share on Social Networks: